Platelet Disease

Navitoclax-d₈ is the d₈-labeled Navitoclax (HY-10087). Navitoclax (ABT-263 ) is an orally active BH3 mimetic and an inhibitor of Bcl-2, Bcl-xL, and Bcl-w, with a K_i value of <1 nM for each target. Navitoclax triggers endogenous Apoptosis and downregulates the expression of Survivin and TGFβ2. Navitoclax alleviates fibrosis and induces thrombocytopenia. Navitoclax exhibits anticancer activity against a variety of tumors and enhances the efficacy of chemotherapy and radiotherapy. Navitoclax can be used in the research of acute lymphoblastic leukemia, ovarian cancer, and fibrotic diseases.

Pirlindole is an orally active, selective and reversible MAO-A inhibitor with an IC₅₀ value of 250 nM. Pirlindole inhibits genomic replication of Enterovirus species B and D, and exhibits moderate activity against enterovirus species A. Pirlindole inhibits MAO-A-mediated monoamine metabolism, promotes adult hippocampal neurogenesis, rescues stress-induced dendritic atrophy of hippocampal granule neurons, reverses behavioral effects associated with chronic mild stress, and also possesses anticonvulsant, analgesic, local anesthetic, hypotensive, antiplatelet aggregation and antispasmodic activities. Pirlindole shows no detectable mutagenic, clastogenic or carcinogenic properties. Pirlindole can be used in research related to depression and enterovirus infections.

Salvianolic acid D is a depside. Salvianolic acid D can be isolated from Salvia miltiorrhiza (Danshen). Salvianolic acid D promotes the expression of Bcl-2, and inhibits the expressions of Bax, Cleaved caspase-3 and -9. Salvianolic acid D reduces the expression levels of TLR4, MyD88 and TRAF6 proteins both in vitro and in vivo, and significantly inhibits the nuclear translocation of NF-κB. Salvianolic acid D inhibits the cytoplasmic translocation of HMGB1. Salvianolic acid D suppresses inflammatory responses and alleviates cerebral ischemia-reperfusion injury. Salvianolic acid D serves as a potential antiplatelet active component.

Fibrinogen-Binding Peptide TFA is a Fibrinogen-binding peptide. Fibrinogen-Binding Peptide TFA inhibits platelet adhesion to vitronectin and fibrinogen. Fibrinogen-Binding Peptide TFA inhibits platelet aggregation in ADP-stimulated platelet-rich plasma and in thrombin-stimulated washed platelets. Fibrinogen-Binding Peptide TFA can be used for research on thrombosis.

Leyk is an orally active Cysteine derivative. Leyk stimulates bone marrow hematopoiesis. Leyk exerts a significant protective effect against cyclophosphamide-induced leukopenia. Leyk can be used in studies related to thrombocytopenia and leukopenia.

Navitoclax dihydrochloride (ABT-263 dihydrochloride) is an orally active BH3 mimetic and an inhibitor of Bcl-2, Bcl-xL, and Bcl-w, with a K_i value of <1 nM for each target. Navitoclax dihydrochloride triggers endogenous Apoptosis and downregulates the expression of Survivin and TGFβ2. Navitoclax dihydrochloride alleviates fibrosis and induces thrombocytopenia. Navitoclax dihydrochloride exhibits anticancer activity against a variety of tumors and enhances the efficacy of chemotherapy and radiotherapy. Navitoclax dihydrochloride can be used in the research of acute lymphoblastic leukemia, ovarian cancer, and fibrotic diseases.

Sutacimig (HMB-001) is a humanized antibody of the (H-γ4_L-κ)_(H-γ4_L-κ) format that targets FⅦa/TREML1. One arm of Sutacimig binds to endogenous FVIIa, thereby prolonging the half-life of FVIIa and increasing its accumulation in the bloodstream, while the other arm binds to TLT-1, which is exclusively expressed on the surface of activated platelets. This localizes endogenous FVIIa to activated platelets, further enhancing the activity of FVIIa. Sutacimig enhances Thrombin generation, fibrin formation, and the formation of stable fibrin-platelet networks at sites of vascular injury. Sutacimig can be used in studies related to Glanzmann thrombasthenia.

INCA033989 is a fully human IgG1 monoclonal antibody targeting mutCALR (K_D = 1.75 nM for mutCALR^del52; K_D = 6.78 nM for mutCALR^ins5). INCA033989 antagonizes mutCALR-driven signaling and proliferation. INCA033989 selectively inhibits pSTAT3/pSTAT5. INCA033989 prevents thrombocytosis and reduces the expansion of mutCALR-positive cells. INCA033989 is useful for research on myeloproliferative neoplasms .

Pirprofen (SU 21524) is an orally active non-steroidal anti-inflammatory agent. pirprofen is a reversible prostaglandin synthetase inhibitor. Pirprofen inhibits leucocyte chemotaxis. Pirprofen shows anti-inflammatory, analgesic, antipyretic, ulcerogenic activities. Pirprofen inhibits the secondary phase of platelet aggregation induced by Collagen and Arachidonic acid (HY-109590). Pirprofen induces hepatitis.

HOOC-PEG2000-COOH is a dicarboxyl-terminated polyethylene glycol and calcium ion chelator. HOOC-PEG2000-COOH inhibits platelet aggregation and contraction while promoting fibrinolysis and blood clot dissolution. HOOC-PEG2000-COOH can serve as a coating for superparamagnetic iron oxide nanoparticles in nanovaccine formulations, and as a bifunctional linker in pH-sensitive conjugates for siRNA delivery liposomes. HOOC-PEG2000-COOH can be used in research on thrombosis and atherosclerosis.

Myrianthic acid is a pentacyclic triterpenoid compound. Myrianthic acid can exist in the root wood of Myrianthus arboreus and the leaves of Campsis grandiflora. Myrianthic acid inhibits adrenaline-induced platelet aggregation, with a IC₅₀ of 46.2 μM for this activity. Myrianthic acid can be used in studies related to thrombosis.

Bis[2-(4-hydroxyphenylthio) ethoxy]methane (DD-70) is a Bisphenol A (HY-18260) substitute and a COX-1 inhibitor. Bis[2-(4-hydroxyphenylthio) ethoxy]methane blocks platelet aggregation induced by Arachidonic acid (HY-109590) and U-46619 (HY-108566). Bis[2-(4-hydroxyphenylthio) ethoxy]methane alters hemostatic function. Bis[2-(4-hydroxyphenylthio) ethoxy]methane reduces embryonic survival rate, decreases embryonic mass and increases gallbladder mass in chicken embryos.

Cochinchinenin C is a GLP-1R agonist that binds to the extracellular domain of the receptor via hydrophobic interactions and hydrogen bonds, and promotes glucose-dependent insulin secretion from pancreatic β-cells. Cochinchinenin C also increases intracellular cAMP and ATP levels. At low concentrations, Cochinchinenin C binds to human serum albumin, alters its microenvironment, and induces dominant static fluorescence quenching. Cochinchinenin C shows almost no cytotoxicity to pancreatic β-cells, and exerts a synergistic effect with Loureirin A (HY-N1505) when binding to human serum albumin. Cochinchinenin C has been widely used in studies of type 2 diabetes, Helicobacter pylori infection, thrombotic diseases, and other conditions.

Pizotifen hydrochloride (Pizotyline hydrochloride) is a 5-HT₂ receptor antagonist. Pizotifen hydrochloride inhibits the Wnt/β-catenin-EMT signaling pathway and induces mitochondria-mediated Apoptosis. Pizotifen hydrochloride causes transient ERK1/2 phosphorylation and restores ATP. Pizotifen hydrochloride blocks Serotonin (HY-B1473A)-mediated platelet activation, inhibits Serotonin-enhanced ADP-induced platelet aggregation, and prolongs carotid artery occlusion and tail bleeding time. Pizotifen hydrochloride exhibits anticancer activity against gastric cancer and colon cancer. Pizotifen hydrochloride exerts neuroprotective effects in the striatum of R6/2 mice. Pizotifen hydrochloride can be used for research on gastric cancer, colon cancer, Huntington's disease, metastasis, and thromboembolic diseases.

Pizotyline-d₃ (BC-105-d₃) is the d₃-labeled Pizotifen (HY-B0115). Pizotifen (Pizotyline) is a 5-HT₂ receptor antagonist. Pizotifen inhibits the Wnt/β-catenin-EMT signaling pathway and induces mitochondria-mediated Apoptosis. Pizotifen causes transient ERK1/2 phosphorylation and restores ATP. Pizotifen blocks Serotonin (HY-B1473A)-mediated platelet activation, inhibits Serotonin-enhanced ADP-induced platelet aggregation, and prolongs carotid artery occlusion and tail bleeding time. Pizotifen exhibits anticancer activity against gastric cancer and colon cancer. Pizotifen exerts neuroprotective effects in the striatum of R6/2 mice. Pizotifen can be used for research on gastric cancer, colon cancer, Huntington's disease, metastasis, and thromboembolic diseases.

Cilinaphthalide B is an integrin αIIbβ3 inhibitor and a phthalide derivative that inhibits platelet aggregation by binding to integrin αIIbβ3 and interfering with the conformational changes required for its activation, and it exhibits cytotoxicity against cancer cell lines. Cilinaphthalide B can be used in antiplatelet and anticancer-related research.

(-)-Isocoreximine is a tetrahydroprotoberberine alkaloid that exhibits inhibitory activity against platelet aggregation. (-)-Isocoreximine can be found in natural sources. (-)-Isocoreximine inhibits platelet aggregation.

(3S,4S)-4-Hydroxy-3,6-dimethyl-3,4-dihydronaphthalen-1 (2H)-one is a tetralone derivative. (3S,4S)-4-Hydroxy-3,6-dimethyl-3,4-dihydronaphthalen-1 (2H)-one shows weak inhibitory activity against arachidonic acid-induced platelet aggregation, and exhibits no positive inotropic activity at the concentration of 10^-5 g/mL.

PDI-IN-4 is a highly selective inhibitor of human PDI (IC₅₀=0.48 μM) with no significant cytotoxicity. PDI-IN-4 binds to PDI in a reversible manner, not only forming a covalent bond with the Cys400 residue but also engaging in hydrophobic interactions with other residues. By inhibiting the activation of GPIIb/IIIa, PDI-IN-4 effectively blocks platelet aggregation and thrombus formation. PDI-IN-4 can serve as an important tool reagent for thrombosis-related research.

Ethaverine hydrochloride (Standard) is the analytical standard of Ethaverine hydrochloride (HY-B1440). This product is intended for research and analytical applications. Ethaverine hydrochloride is a Papaverine derivative and vasodilator. Ethaverine hydrochloride inhibits Phosphodiesterase, Tyrosine hydroxylase, and MAO-B. Ethaverine hydrochloride blocks L-type Ca²⁺ channels, reduces intracellular Ca²⁺ levels, inhibits platelet adhesion and aggregation, regulates cardiac conduction and heart rate, and increases peripheral and cerebral blood flow. Ethaverine hydrochloride alters cochlear microcirculation, intracochlear Po₂, CM potential, and EP in guinea pigs, and induces transient hypotension. Ethaverine hydrochloride is used in the research of peripheral vascular diseases.